-transparent.png){kind=logo}
Serum levels of CA15-3, a mammary tumor associated antigen recognized by two different murine monoclonal antibodies (115D8 and DF3), were investigated in patients with mammary carcinoma and other benign or malignant diseases. The reference value of the serum CA15-3 level was obtained as 24 units/ml at the 99% confidence limit among healthy individuals (n = 462). Elevation of serum CA15-3 levels was observed in 24.3% of overall patients with mammary carcinoma. Serum CA15-3 levels in breast cancer patients correlated with the clinical stage; higher percentages of positivity were observed in those with advanced breast cancer (stage IV, 64.7%, recurrent, 52.4% and metastatic, 70.3%). Furthermore, elevated serum CA15-3 levels in breast cancer patients responded well to the effect of therapy. Although the serum CA15-3 test gave percentages of positivity of breast cancer similar to those found by the serum CEA test, the serum CA15-3 test revealed lower percentages of positivity than the serum CEA test among patients with benign breast lesions, liver cirrhosis or other carcinomas. These results suggest that the serum CA15-3 antigen level provides a very useful marker for diagnosis and clinical monitoring of patients with breast cancer.
N Fujino, and
Y Haga, and
K Sakamoto, and
H Egami, and
M Kimura, and
R Nishimura, and
M Akagi
July 1992,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
N Fujino, and
Y Haga, and
K Sakamoto, and
H Egami, and
M Kimura, and
R Nishimura, and
M Akagi
January 1987,
Cancer,
N Fujino, and
Y Haga, and
K Sakamoto, and
H Egami, and
M Kimura, and
R Nishimura, and
M Akagi
March 1998,
Zhonghua zhong liu za zhi [Chinese journal of oncology],
N Fujino, and
Y Haga, and
K Sakamoto, and
H Egami, and
M Kimura, and
R Nishimura, and
M Akagi
October 1986,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
N Fujino, and
Y Haga, and
K Sakamoto, and
H Egami, and
M Kimura, and
R Nishimura, and
M Akagi
July 1988,
Cancer research,
N Fujino, and
Y Haga, and
K Sakamoto, and
H Egami, and
M Kimura, and
R Nishimura, and
M Akagi
April 1989,
Clinical chemistry,
N Fujino, and
Y Haga, and
K Sakamoto, and
H Egami, and
M Kimura, and
R Nishimura, and
M Akagi
October 1973,
Journal of the National Cancer Institute,
N Fujino, and
Y Haga, and
K Sakamoto, and
H Egami, and
M Kimura, and
R Nishimura, and
M Akagi
February 1974,
Virginia medical monthly,
N Fujino, and
Y Haga, and
K Sakamoto, and
H Egami, and
M Kimura, and
R Nishimura, and
M Akagi
March 1984,
Cancer research,
N Fujino, and
Y Haga, and
K Sakamoto, and
H Egami, and
M Kimura, and
R Nishimura, and
M Akagi
October 1987,
Indian journal of pathology & microbiology,
